Stoke Therapeutics announces CEO transition

US biotech Stoke Therapeutics (Nasdaq: STOK), which is dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, yesterday revealed that Dr Edward Kaye has decided to step down from his role as chief executive (CEO) effective as of March 19, 2025. The firm’s shares dipped 3% following the announcement.

To facilitate a smooth transition, Dr Kaye will serve as an advisor to the company and will continue to serve as a director on Stoke’s board. Effective March 19, Ian Smith has been appointed interim CEO. The current chairman of the board, Arthur Tzianabos, has been appointed interim executive chairman. He will support Mr Smith and Dr Kaye through the transition and lead the search for a permanent CEO.

Dr Tzianabos said: “On behalf of the board, I would like to thank Ed for his invaluable contributions to Stoke over the last seven years. Ed’s vision and experience were instrumental in translating Stoke’s science into a first-in-class potential disease-modifying medicine for Dravet syndrome. Ed successfully led the company from a start-up through many key development milestones, creating a strong foundation for continued success and future growth as we enter late-stage clinical development and prepare for commercialization. We look forward to continuing to benefit from Ed’s expertise as a board member and advisor.”